Trials / Unknown
UnknownNCT04173390
PREemptive Analgesia With preGABAlin in HEART Surgery
Preemptive Analgesia With Pregabalin in Heart Surgery: a Randomized Clinical Trial
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 230 (estimated)
- Sponsor
- InCor Heart Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
BACKGROUND: Postoperative pain after cardiac surgery has high incidence and is associated with worse morbidity. Pregabalin is a new antiepileptic drug used in patients with chronic pain and has been studied even more in postoperative. OBJECTIVE: Evaluate whether preemptive pregabalin use compared with placebo decreases pain perception in patients undergoing cardiac surgery in the first 24 hours and 2 months after hospital discharge; evaluate analgesic consumption in the immediate postoperative period; evaluate differences in blood gas parameters between groups; evaluate anesthetic recovery by QoR-40; assess incidence of serious adverse events (reintubation and mental confusion); incidence of delirium through the CAM-ICU questionnaire; assess adverse drug events (nausea, vomiting, pharmacodermia, allergic reactions). METHOD: Randomized, triple-blind, placebo-controlled clinical trial. EXPECTED RESULTS: Postoperative pain control with a drug that could cause fewer side effects, may lead to faster clinical improvement, fewer medications and fewer procedures, and lower healthcare costs with a decrease in intensive care unit (ICU) stay.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pregabalin 150mg | Preemptive use of pregabalin 150 mg starting three days before surgery up to the third postoperative day |
| DRUG | Placebo oral tablet | Preemptive use of Placebo oral tablet starting three days before surgery up to the third postoperative day |
Timeline
- Start date
- 2021-03-01
- Primary completion
- 2021-12-31
- Completion
- 2023-11-01
- First posted
- 2019-11-21
- Last updated
- 2021-02-23
Locations
2 sites across 1 country: Brazil
Source: ClinicalTrials.gov record NCT04173390. Inclusion in this directory is not an endorsement.